Medicare Part D - The product of a broken process
Article Abstract:
Medicare Part D, the new prescription-drug coverage under Medicare launched in the US on January 1, 2006, has achieved few of its original goals. The main problems with the drug benefit are that drug-company and health insurance lobbyists heavily influenced the final legislation passed by Congress, thus focusing mainly on the needs of those industries instead of those of the seniors it should serve.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
The new Medicare prescription-drug legislation
Article Abstract:
A summary of the prescription drug benefit passed by Congress is presented. Although the program will help many seniors to pay for needed medications, it may have no effect on drug prices. The actual plan does not go into effect until 2006, and the plan may change if the 2004 elections change the party that controls Congress.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Bolstering the FDA's drug-safety authority
Article Abstract:
The basic provisions in the Food and Drug Administration Amendments act (FDAAA), drug safety bill which was signed into law on September 27, 2007 are reviewed.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Reaping rewards of loyalty. The return of a forgotten foe: Measles outbreaks spur caution
- Abstracts: The price of a physician practice. Boston's backyard
- Abstracts: Medicare pilot project offers CME for quality improvement . Medicare computers ripe for upgrade
- Abstracts: Low-dose aspirin for the prevention of atherothrombosis. Daily aspirin--only half the answer. Efficacy and safety of low-dose aspirin in polycythemia vera
- Abstracts: Brief report: idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells and airways disease. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis